PT - JOURNAL ARTICLE AU - Johann Bartko AU - Christian Schoergenhofer AU - Michael Schwameis AU - Patricia Wadowski AU - Jacek Kubica AU - Bernd Jilma AU - Eva-Luise Hobl TI - Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers AID - 10.1124/jpet.117.247213 DP - 2018 May 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 430--436 VI - 365 IP - 2 4099 - http://jpet.aspetjournals.org/content/365/2/430.short 4100 - http://jpet.aspetjournals.org/content/365/2/430.full SO - J Pharmacol Exp Ther2018 May 01; 365 AB - Aspirin is a cornerstone in the antiplatelet therapy for acute coronary syndromes. Coadministration of morphine may potentially influence the intestinal absorption, pharmacokinetics, and pharmacodynamics, as seen with P2Y12 inhibitors. In this trial, healthy volunteers were randomized to receive morphine (5 mg, i.v. bolus injection) at one of seven different time points before, after, or with aspirin (162 mg, p.o.) in a double-blind, placebo-controlled fashion. After a 14-day washout, subjects received placebo instead of morphine. Pharmacokinetics were determined by liquid chromatography, and aspirin’s effects were measured by platelet function tests (whole-blood platelet aggregation: multiplate, platelet plug formation: PFA-100). Morphine increased the total acetylsalicylic acid exposure by 20% compared with placebo when given simultaneously with aspirin, whereas Cmax and tmax were not altered. Morphine had no significant effect on aspirin-induced platelet inhibition. In contrast to coadministration with P2Y12 inhibitors, morphine appears to have negligible interaction with aspirin.